trending Market Intelligence /marketintelligence/en/news-insights/trending/StCVeC4AMHAE_4DtC5X0Tg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Approval for Astrazeneca, Merck & Co.; designation for Savara

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Approval for Astrazeneca, Merck & Co.; designation for Savara

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Jan. 3.

Approvals

* AstraZeneca PLC and Merck & Co. Inc.'s Lynparza as a stand-alone maintenance therapy for BRCA-mutated pancreatic cancer that has spread but has not progressed for at least 16 weeks following first-line platinum-based chemotherapy.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: AP Photo

Breakthrough therapy

* Savara Inc.'s Molgradex for autoimmune pulmonary alveolar proteinosis.